Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 1/03/13$

	of entity	
MAST	TERMYNE GROUP LIMITED	
ABN		
96 142	2 490 579	
Part	he entity) give ASX the following 1 - All issues set complete the relevant sections (attach	
10u mu	ist complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Performance Rights
	Number of *securities issued or	253,111

⁺ See chapter 19 for defined terms.

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Rights to acquire ordinary shares in the Company, subject to achievement of performance measures (hurdles), issued to the Executive Management team including the Managing Director.

General Terms & Conditions of the Performance Rights are contained in the Company's Employee Performance Rights Plan with specific information relating to the Managing Director's issue detailed in an Offer Deed, as advised to shareholders in the Notice of Annual General Meeting and approved 20 November 2018.

Performance Rights granted to the Executive Management are on the same terms to those granted to the Managing Director as advised to shareholders in the Notice of Annual General Meeting and approved 20 November 2018.

Rights granted as follows: 117,959 to the Managing Director 135,152 to the remainder of the Executive Management Team

Exercise Price: Nil

Expiry Date: 1 October 2021

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

As this is an issue of Performance Rights that aren't quoted securities, they do not rank equally with ordinary shares, or have the right to vote, receive dividends or any other rights of a shareholder.

If the Performance Rights vest on 1 October 2021, shares issued on exercise of the Performance Rights will rank equally with all other issued shares, including for dividends.

5 Issue price or consideration

Nil. The eligible participants will be entitled to receive one ordinary share in the company without payment for each Performance Right that vests.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) The Company has established an Employee Performance Rights Plan to provide senior executives and staff with an incentive to improve the performance of the Company and the Company's share price.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

6c Number of *securities issued without security holder approval under rule 7.1

Yes

20 November 2018

Nil

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	Nil	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	253,111	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Not Applicable	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not Applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	15,163,193 under rule 7. 10,108,753 under listing	
7	+Issue dates	21/11/18	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.		
	3 11		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	101,087,536	Ordinary Shares

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

Number	+Class
Total on issue of	Performance Rights
1,890,334 (which	covering different
includes an	periods, prices and
adjustment for	hurdles, with
74,237 performance	maximum expiry 1
rights which have	October 2021
lapsed due to	
employee	
resignations)	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged			

Part 2 - Pro rata issue

11	Is security holder approval required?	NOT APPLICABLE
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

	_	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
	of commission	
22	Names of any brokers to the issue	
	L	
23	Fee or commission payable to the	
	broker to the issue	
24	Amount of any handling fee	
•	payable to brokers who lodge	
	acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on	
	security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be	
	sent to persons entitled	
	_	
27	If the entity has issued options, and the terms entitle option	
	holders to participate on exercise,	
	the date on which notices will be	
	sent to option holders	
28	Date rights trading will begin (if	
	applicable)	
29	Date rights trading will end (if	
-9	applicable)	
	L	
30	How do security holders sell their	
	entitlements in full through a broker?	
	oroner.	
31	How do security holders sell <i>part</i>	
	of their entitlements through a broker and accept for the	
	balance?	

⁺ See chapter 19 for defined terms.

Appendix 3B	
New issue and	nouncement

				_
32	of the	do security holders dispose eir entitlements (except by nrough a broker)?		
33	⁺Issu€	e date		
	•	notation of securities mplete this section if you are app		^f securities
34	Type (tick o	of *securities one)	NOT APPLICA	BLE
(a)		⁺ Securities described in Part	İ 1	
(b)		•	•	l, partly paid securities that become fully paid, ies issued on expiry or conversion of convertible
Entitie	s that	have ticked box 34(a)		
Additi	onal s	ecurities forming a new	class of securiti	es
Tick to docume		e you are providing the informat	tion or	NOT APPLICABLE
35				nes of the 20 largest holders of the ercentage of additional *securities
36		If the *securities are *equity *securities setting out the no 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		bution schedule of the additional the categories
37		A copy of any trust deed for	the additional ⁺ sec	urities

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b) **NOT APPLICABLE** 38 Number of *securities for which ⁺quotation is sought *Class of *securities for which 39 quotation is sought Do the *securities rank equally in 40 all respects from the +issue date with an existing +class of quoted *securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security) Number +Class Number and +class of 42 all *securities quoted on ASX (including the *securities in clause 38)

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the †securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Brett Maff	Date:21/11/2018
21 6 11 1161 611 111	(Company secretary)	2 466=1, 11, 1010
Print name:		

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
 Add the following: Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	Nil	
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period		
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil	
"A"	101,087,536	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	15,163,193	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Nil	
• Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	0	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	-	
"A" x 0.15	15,163,193	
Note: number must be same as shown in Step 2		
Subtract "C"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	15,163,193	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	101,087,536	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	10,108,753	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
 Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	Nil	
"E"	Nil	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	10,108,753
Subtract "E" Note: number must be same as shown in Step 3	Nil
<i>Total</i> ["A" x 0.10] – "E"	10,108,753 Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.